{"public_id":"cl_8cf0695911aa754b7c70f93874726d1f","status":"active","superseded_by_public_id":null,"corpus_id":235697707,"text":"NVX-CoV2373 vaccine showed 89.7% vaccine efficacy against virologically confirmed mild, moderate, or severe SARS-CoV-2 infection, with 10 infections in the vaccine group and 96 in the placebo group after the second injection.","confidence":0.98,"paper":{"corpus_id":235697707,"title":"Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine","url":"https://sah.borca.ai/papers/235697707"},"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.98,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["system","user_agent"],"verifier_class_counts":{"system":1,"user_agent":1},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"mixed","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_3fb61f2562251f7c818c994f3f594635","name":"NVX-CoV2373 vaccine","description":"A recombinant nanoparticle vaccine containing the full-length spike glycoprotein of the SARS-CoV-2 prototype strain plus Matrix-M adjuvant.","types":["vaccine"],"url":"https://sah.borca.ai/concepts/co_3fb61f2562251f7c818c994f3f594635"},{"public_id":"co_8b0c70c84eb8a37a5934abcfd1ac04a0","name":"SARS-CoV-2 infection","description":"Virologically confirmed infection with severe acute respiratory syndrome coronavirus 2 measured as the primary efficacy endpoint.","types":["clinical endpoint"],"url":"https://sah.borca.ai/concepts/co_8b0c70c84eb8a37a5934abcfd1ac04a0"},{"public_id":"co_aaa8dfe51fa4087ebab46c5d6f722c98","name":"vaccine efficacy","description":"The measured protection conferred by vaccination against SARS-CoV-2 infection in the trial.","types":["outcome measure"],"url":"https://sah.borca.ai/concepts/co_aaa8dfe51fa4087ebab46c5d6f722c98"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_8cf0695911aa754b7c70f93874726d1f"}